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Abstract
The existence of effective therapies for most cardiovascular disease states, coupled with increased
requirements that potential benefits of new drugs be evaluated on clinical rather than surrogate
endpoints, makes it increasingly difficult to substantiate any incremental improvements in efficacy
that these new drugs might offer. Compounding the problem is the highly controversial issue of
comparing new agents with placebos rather than active pharmaceuticals in drug efficacy trials.
Despite the recent consensus that placebos may be used ethically in well-defined, justifiable
circumstances, the problem persists, in part because of increased scrutiny by ethics committees but
also because of considerable lingering disagreement regarding the propriety and scientific value of
placebo-controlled trials (and trials of antihypertensive drugs in particular).
The disagreement also substantially affects the most viable alternative to placebo-controlled trials:
actively controlled equivalence/noninferiority trials. To a great extent, this situation was prompted
by numerous previous trials of this type that were marked by fundamental methodological flaws
and consequent false claims, inconsistencies, and potential harm to patients.
As the development and use of generic drugs continue to escalate, along with concurrent pressure
to control medical costs by substituting less-expensive therapies for established ones, any claim
that a new drug, intervention, or therapy is "equivalent" to another should not be accepted without
close scrutiny. Adherence to proper methods in conducting studies of equivalence will help
investigators to avoid false claims and inconsistencies. These matters will be addressed in the third
article of this three-part series.
The Magnitude and Scope of the Background 
Problem
The cardiovascular therapeutic area
The cardiovascular indication has been the largest or sec-
ond-largest focus of clinical trials for the past decade (the
central nervous system has occupied first place since
1999), making up 15.5% of all clinical investigator con-
tracts[1] Correspondingly, the cardiovascular therapeutic
area commands the largest market for prescription drugs
– nearly one fourth of branded prescription drug sales – as
the dominant indication for branded medicines sold
commercially during the past few years. The total world-
wide cardiovascular market is expected to show revenues
of $91.2 billion in 2008, an increase of 6.9% compared
with 2003 [2]
The WHO ICD-9 coding system specifies 46 cardiovascu-
lar diseases within this therapeutic area; however, 65% of
all cardiovascular trials address the top six of these
subindications. Essential hypertension is in first place
(27.1% of trials), followed by congestive heart failure
(13.1%) and cerebrovascular disease (9.9%).
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The public health impact
The above mentioned figures are more than justified by
the impressive ranking identifying cardiovascular disease
as the dominant cause of death and disability worldwide
[3] Cardiovascular disease remains a massive public
health problem in the developed world, not only in terms
of survival, but also with regard to work capacity [4] In the
US alone, more than 10 million individuals have sympto-
matic coronary heart disease, and up to 70% of older
adults have hypertension [5] resulting each year in
approximately 1.5 million myocardial infarctions, nearly
1 million deaths, and an economic burden of $12 billion.
According to WHO figures, [6] cardiovascular disease kills
an estimated 17 million people worldwide each year, and
it will remain the primary cause of overall mortality for
the foreseeable future.
Demographic changes
This latter trend is at least in part a reflection of a world-
wide demographic explosion – a huge increase in the
number of older adults as a result of unprecedented gains
in life expectancy. Globally, the population of people over
65 years of age is increasing by 750,000 each month. The
older population is expected to triple in many developing
countries within the next 30 years [7]
The aging of the population is beginning to transform
health care and social systems, as new public policies in
health and social care are being widely adopted through-
out the world. [8-11] Public interest and discussions of
healthcare issues are at an all-time high. Because the cost
of health care is continually escalating in both developed
in developing countries, the trend is toward structural
reform of healthcare systems.
Spending on prescription drugs
Maintaining a balance between healthcare costs and
income is the biggest challenge faced by the majority of
markets worldwide. The discrepancy between what is pos-
sible today in the provision modern healthcare and what
is affordable within limited budgets continues to grow.
Politicians, healthcare authorities, hospital administra-
tors, and providers are all looking for cost-containment
strategies and additional sources of financing in an effort
to curb rising healthcare debts and costs at a time when
the proportion of gross domestic product (GDP) allocated
to healthcare spending has remained static or is about to
fall in many countries.
The percent increase in annual spending for prescription
drugs has reached double-digits for the past several years,
making drugs increasingly unaffordable. These expendi-
tures represent the fastest-growing component of health
care, accounting for 10% to 30% of total healthcare
spending in most countries (10% in the US, equalling a
15% increase per year over the past several years,[12] to
30% in Slovakia and Bulgaria[13]). It is estimated that
prescription drug expenditures will continue to rise faster
than any other service medical sector in most countries
over the next decade and to represent 15% of total
national health spending in the US by the year 2010 [12]
From January to June 2003, the number of prescriptions
issued in the UK was 631.7 million, an increase of 21.6%
since 1999–2000; this increase in prescriptions was asso-
ciated with a 45.9% increase in drug costs to £7,182.2 mil-
lion over the same 3-year period. Between June 2002 and
June 2003, prescription costs increased by 11.1%, whereas
the number of prescription items increased by 5.4% [14]
This trend has already had an impact on public insurance
programs and triggered considerable political attention in
recent years, as healthcare cost containment has become a
priority on the political agenda of governments seeking to
curb the spiralling debt.
The profile of spending/sales
Of the 9,532 registered drugs on the US market, the bulk
of the 1-year spending growth of $22.5 billion in 2001
was largely attributable to increased spending on a rather
small number of individual drugs and categories of
drugs[15]:
• Just over half (50.6%) of the growth in spending
occurred in just nine categories of drugs – those used for
treating depression, high cholesterol, diabetes, arthritis,
high blood pressure, pain, allergies, and ulcers and other
gastrointestinal ailments.
• Among the 50 drugs that contributed most to the 1-year
increase in spending, sales rose by 43.3%. Sales of all
other drugs (9,482 in the retail market) rose by 6.7%. The
numbers of prescriptions written for the top 50 drugs rose
by 31.7%; by comparison, the increase was 2.2% for all
other drugs.
The paradigm shift of drug discovery
Against this background comes an explosion of potential
new therapies. Over the next decade, combinatorial chem-
istry, genomics, and proteomics[16] will likely unleash an
exponentially greater number of therapeutics into the
development pipeline. These new agents will have the
potential to further increase the complexity of today's
drug expenditures and, no doubt, considerably increase
the cost of drug-development programs.
For the time being, however, spending by the pharmaceu-
tical industry on research and development (R&D) is
driven by several factors [17] The first is the increasing cost
of bringing a new chemical entity to the market, approxi-
mately $500 to $800 million by current estimates. ThisCurrent Controlled Trials in Cardiovascular Medicine 2004, 5 http://cvm.controlled-trials.com/content/5/1/4
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rising cost is generated not by inflation alone, but prima-
rily, by the increased complexity of current drug develop-
ment. In contrast to the situation in past decades, a
growing proportion of modern drugs are intended to be
used for an extended or even an indefinite period (i.e.,
they will be taken daily to treat such chronic conditions as
hypertension, hypercholesterolemia, diabetes, and neu-
ropsychiatric diseases). Because these drugs are suppos-
edly free of, or almost, free of side effects they are
advantageous for use by the elderly, many of whom take
several different drugs simultaneously, thereby increasing
the risk of harmful drug interactions.
The main challenge faced by pharmaceutical companies –
to reduce time to market and time to peak sales – is
accomplished by three measures:
• Increasing the number of new molecular entities in the
pipelines of the pharmaceutical industry's R&D depart-
ments (The number of compounds under development
by the US pharmaceutical industry between 1995 and
1999 increased by 35%, to 7,434; however, the number of
product launches declined 22%, to 56, during the same
period.)
• Productivity advances with the potential to generate new
and better leads in a range of therapeutic areas (The ability
to conduct high-throughput screening of compounds
increased from approximately 3 to 4 million data points
in 1998, to 150 million data points in 2002.)
• Aggressive and relentless marketing of new products to
physicians and consumers alike.
The Problems
Drug safety issues
According to estimates, the drugs that are most commonly
used are effective in only 30% to 60% of patients with the
same disease. Additionally, a subset of these patients may
encounter severe side effects. Adverse drug reactions were
reported to be the 4th to 6th leading cause of death in the
US in 1994, resulting in 106,000 fatalities and having a
$100 billion financial impact that year [18] In 1998,
108,000 Americans died from adverse reactions to FDA-
approved drugs, properly administered by licensed medi-
cal professionals. In the same year, 2.2 million Americans
had adverse reactions to approved drugs [19-22]
The pro-patient and public health expectations
One of the most visible organizations in the broad coali-
tion of pro-patient groups is the Medicines in Europe
Forum,[23] a Paris-based group of scientists and political
activists. As a counterpoint to industry views on how EU
rules should be changed, the forum has been calling
loudly for "a policy of medicines that puts patients first."
Among the forum's most strongly expressed complaints is
that "many new medicines are sold without having been
compared to the most appropriate drugs for the same dis-
ease already available on the market." The remedy, it
argues, is for independent information to be compiled
and disseminated. "Health authorities must be able to
supply comparative information on the added therapeutic
value of new medicines – or on the lack of it," it says, and
"this information can be obtained only if the appropriate
clinical trials are carried out."
The UK charitable foundation known as the King's
Fund[24] has published a new report expressing the fol-
lowing views with reference to the UK government's rela-
tionship with the pharmaceutical industry: "We want to
see a relationship develop between government and the
pharmaceutical industry that is geared towards the pro-
motion of health, not just the promotion of wealth. For
too long, the pharmaceutical industry has been in the
driving seat of this relationship, with the government act-
ing as a passive purchaser of drugs."
Physicians' behaviour
Better decision-making by physicians has been long con-
sidered a means of materially improving the balance
between benefits and harm in health care, while saving
billions of dollars. However, the much-anticipated
changes in the behavior patterns of physicians have never
taken place, at least not in the desired direction. Physi-
cians today operate under increasing political and eco-
nomic pressure, while they process ever-increasing
amounts of evolving evidence in the context of their own
unique micro- and macro-sociology, where the economic
incentives are not infrequently perverse. They must indi-
vidualize therapy and consider combinations of drugs for
which randomized evidence may be limited. In parallel,
third-party payers are pressing for drug cost containment,
patients' expectations are increasing rapidly, and medico-
legal pitfalls are omnipresent [25]
The fiscal intermediaries
A tiny light, however, is visible at the end of the tunnel.
Sooner or later, pharmacogenetics will make possible the
tailoring of drug prescribing to the individual patient's
biology, aligning at last the great diversity of desires
among the many stakeholders in the healthcare business.
Until that evolutionary point is achieved, however, differ-
ent solutions have been implemented, or are about to be
implemented, in the US and many European countries.
The most radical and highly controversial of these solu-
tions, applied on both sides of the Atlantic, is generic sub-
stitution, or therapeutic substitution of drugs. This term
refers to the dispensing of an alternate chemical entity
from the same general therapeutic class as that of the orig-Current Controlled Trials in Cardiovascular Medicine 2004, 5 http://cvm.controlled-trials.com/content/5/1/4
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inal drug prescribed by the physician. The act of substitu-
tion dispensing is carried out by a group of, so far,
relatively neutral stakeholders in the business – the phar-
macy benefit managers, who act as fiscal intermediaries
that administer pharmacy benefits for employers, health
insurers, and health maintenance organizations [26,27]
The American Heart Association and the American Col-
lege of Cardiology have formally and vigorously opposed
therapeutic substitution, arguing that integration of the
medical history, physical status, and the disease process
relevant to a particular patient is the province and respon-
sibility of that patient's physician [28] Furthermore, ther-
apeutic substitution may result in the patient's receiving a
drug that might not be effective, might produce life-
threatening toxicity, and might interact adversely with
other drugs the patient is receiving. [29-32] Therapeutic
substitution is also opposed by the American Medical
Association, the World Medical Association, and the
American Academy of Family Physician.
The rationale behind the widespread practice of generic
substitution is the class effect concept. The term has never
been defined scientifically, clinically, or from a regulatory
perspective [33] Its oversimplified and inappropriate use
is a dangerous practice that is incompatible with evidence-
based medicine.
Objectives of drug assessment
Regulatory agencies such as the FDA and the European
Agency for the Evaluation of Medicinal Products (EMEA)
have instituted extensive, stringent requirements for drug
development. These requirements include multilevel pre-
marketing reviews and approval processes, as well as post-
marketing programs to gather data on, and assess risks
related to the use of drugs in the general population.
Quality, efficacy, and safety are sine qua non conditions for
the approval of a new drug for marketing [34] A relevant
FDA document[31] emphasizes that "A safe medical prod-
uct is one that has reasonable risks, given the magnitude
of the benefit expected and the alternatives available."
That is, when a new drug is released, its efficacy is sup-
posed to have been well quantified as comparable to that
of "alternatives available" (i.e., to drugs in the same class,
with the same indications, that are already on the market).
In reality, however, when new drugs are released, little
information exists on how they compare with drugs
already used for the same indications [35] With the cur-
rent regulatory requirement of evidence from two pla-
cebo-controlled trials for licensing purposes (sometimes
from one trial),[36,37] the evidence available for the new
drug is limited to its performance in specified experimen-
tal conditions (i.e., relative efficacy), while and in most
cases, evidence regarding its comparability with existing
drugs is nil.
The saying "better than nothing is better than no treat-
ment," derived from placebo-based studies, might be an
acceptable compromise in many cases. However, the full
evaluation of placebo-controlled drugs requires clear
answers to a number of questions. If the new drug is not
better than the old one, then what are its obvious advan-
tages? Is it considerably cheaper, better tolerated, safer, or
easier to administer?[38] These sorts of questions have
focused increased attention to the use of cost-effectiveness
evaluations from early clinical trial stages [38] Unfortu-
nately, this type of evidence is lacking in most cases at the
time of marketing approval. This, together with the, some-
times, questionable efficacy demonstrated through "sta-
tistically significant difference from placebo," [39-42]
leaves the prescribing physicians with a difficult task when
attempting to make informed choices.
The potential solution
This longstanding problem persists despite numerous
guidelines, including the E10 document[44] stipulating
that new medicines should be tested versus existing alter-
native drugs rather than compared to placebos. In this
context, equivalence/noninferiority trials may be valuable
in future marketing authorizations, at least in carefully
selected circumstances. Despite raising complex and trou-
blesome issues, such trials may provide prescribing physi-
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